Association between the DRB1*08032 Histocompatibility Antigen and Methimazole-Induced Agranulocytosis in Japanese Patients with Graves Disease
Authors: Hajime Tamai, Tohru Sudo, Akinori Kimura, Toshio Mukuta, Sunao Matsubayashi, Kanji Kuma, Shigenobu Nagataki, Takehiko Sasazuki
Journal: Annals of Internal Medicine (1996)

Brief Communications1 March 1996Association between the DRB1*08032 Histocompatibility Antigen and Methimazole-Induced Agranulocytosis in Japanese Patients with Graves DiseaseHajime Tamai, MD, Tohru Sudo, MD, Akinori Kimura, MD, Toshio Mukuta, MD, Sunao Matsubayashi, MD, Kanji Kuma, MD, Shigenobu Nagataki, MD, and Takehiko Sasazuki, MDHajime Tamai, MDFrom Kyushu University, Fukuoka, Japan; Tokyo Medical and Dental University, Tokyo, Japan; Kuma Hospital, Kobe, Japan; and Nagasaki University School of Medicine, Nagasaki, Japan., Tohru Sudo, MDFrom Kyushu University, Fukuoka, Japan; Tokyo Medical and Dental University, Tokyo, Japan; Kuma Hospital, Kobe, Japan; and Nagasaki University School of Medicine, Nagasaki, Japan., Akinori Kimura, MDFrom Kyushu University, Fukuoka, Japan; Tokyo Medical and Dental University, Tokyo, Japan; Kuma Hospital, Kobe, Japan; and Nagasaki University School of Medicine, Nagasaki, Japan., Toshio Mukuta, MDFrom Kyushu University, Fukuoka, Japan; Tokyo Medical and Dental University, Tokyo, Japan; Kuma Hospital, Kobe, Japan; and Nagasaki University School of Medicine, Nagasaki, Japan., Sunao Matsubayashi, MDFrom Kyushu University, Fukuoka, Japan; Tokyo Medical and Dental University, Tokyo, Japan; Kuma Hospital, Kobe, Japan; and Nagasaki University School of Medicine, Nagasaki, Japan., Kanji Kuma, MDFrom Kyushu University, Fukuoka, Japan; Tokyo Medical and Dental University, Tokyo, Japan; Kuma Hospital, Kobe, Japan; and Nagasaki University School of Medicine, Nagasaki, Japan., Shigenobu Nagataki, MDFrom Kyushu University, Fukuoka, Japan; Tokyo Medical and Dental University, Tokyo, Japan; Kuma Hospital, Kobe, Japan; and Nagasaki University School of Medicine, Nagasaki, Japan., and Takehiko Sasazuki, MDFrom Kyushu University, Fukuoka, Japan; Tokyo Medical and Dental University, Tokyo, Japan; Kuma Hospital, Kobe, Japan; and Nagasaki University School of Medicine, Nagasaki, Japan.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-124-5-199603010-00005 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Objective: To determine the association between HLA class II genes and methimazole-induced agranulocytosis in patients with Graves disease.Design: Case-control study.Setting: Kuma Hospital, which specializes in thyroid diseases, in Kobe, Japan.Subjects: 24 patients with Graves disease who had methimazole-induced agranulocytosis diagnosed by peripheral granulocyte counts of less than 0.5 × 109/L, and 68 patients with Graves disease treated with methimazole, who were free from agranulocytosis. Controls were 525 healthy, unrelated Japanese student volunteers at Kyushu University in Japan.Measurements: All HLA class II genes were analyzed for polymorphisms at the DNA level by using the polymerase chain reaction ...References1. Cooper DS. Antithyroid drugs. N Engl J Med. 1984; 311:1353-62. Google Scholar2. Moore ED. Toxic manifestations of thiouracil therapy. JAMA. 1946; 130:315-9. Google Scholar3. Trotter WR. The relative toxicity of antithyroid drugs. Journal of New Drugs. 1962; 2:333-43. Google Scholar4. Amrhein JA, Kenny FM, Ross D. Granulocytopenia, lupus-like syndrome, and other complications of propylthiouracil therapy. J Pediatr. 1970; 76:54-63. Google Scholar5. McGavack TH, Chevally J. Untoward hematologic responses to the antithyroid compounds. Am J Med. 1954; 17:36-40. Google Scholar6. Rosove MH. Agranulocytosis and antithyroid drugs. West J Med. 1977; 126:339-43. Google Scholar7. Cooper DS, Goldminz D, Levin AA, Ladenson PW, Daniels GH, Molitch ME, et al. Agranulocytosis associated with antithyroid drugs: effects of patient age and drug dose. Ann Intern Med. 1983; 98:26-9. Google Scholar8. Tamai H, Takaichi Y, Morita T, Komaki G, Matsubayashi S, Kuma K, et al. Methimazole-induced agranulocytosis in Japanese patients with Graves' disease. Clin Endocrinol. 1989; 30:525-30. Google Scholar9. Heinrich B, Gross M, Goebel FD. Methimazole-induced agranulocytosis and granulocyte-colony stimulating factor [Letter]. Ann Intern Med. 1989; 111:621-2. Google Scholar10. Tamai H, Mukuta T, Matsubayashi S, Fukata S, Komaki G, Kuma K, et al. Treatment of methimazole-induced agranulocytosis using recombinant human granulocyte colony-stimulating factor (rhG-CSF). J Clin Endocrinol Metab. 1993; 77:1356-60. Google Scholar11. Walzer RA, Einbinder J. Immunoleukopenia as an aspect of hypersensitivity to propylthiouracil. JAMA. 1963; 148:743-6. Google Scholar12. McIntyre PA, Laleli YR, Hodkinson BA, Wagner HN Jr. Evidence for anti-leukocyte antibodies as a mechanism for drug-induced agranulocytosis. Trans Assoc Am Physicians. 1971; 84:217-28. Google Scholar13. Bilezikian SB, Laleli Y, Tsan MF, Hodkinson BA, Ice S, McIntyre PA. Immunological: reactions involving leukocytes: III. Agranulocytosis induced by antithyroid drugs. Johns Hopkins Med J. 1976; 138:124-9. Google Scholar14. Weitzman SA, Stossel TP. Drug-induced immunological neutropenia. Lancet. 1978; 1:1068-72. Google Scholar15. Berkman EM, Orlin JM, Wolfsdorf J. An anti-neutrophil antibody associated with a propylthiouracil-induced lupus-like syndrome. Transfusion. 1983; 23:135-8. Google Scholar16. Guffy MM, Goeken NE, Burns CP. Granulocytotoxic antibodies in a patient with propylthiouracil-induced agranulocytosis. Arch Intern Med. 1984; 144:1687-8. Google Scholar17. Wall JR, Fang SL, Kuroki T, Ingbar SH, Braverman LE. In vitro immunoreactivity to propylthiouracil, methimazole, and carbimazole in patients with Graves' disease: a possible cause of antithyroid drug-induced agranulocytosis. J Clin Endocrinol Metab. 1984; 58:868-72. Google Scholar18. Sato K, Miyakawa M, Han DC, Kato S, Shibagaki Y, Tsushima T, et al. Graves' disease with neutropenia and marked splenomegaly: autoimmune neutropenia due to propylthiouracil. J Endocrinol Invest. 1985; 8:551-5. Google Scholar19. Fibbe WE, Claas FH, van der Star-Dijkstra W, Schaafsma MR, Meyboom RH, Falkenburg JH. Agranulocytosis induced by propylthiouracil: evidence of a drug dependent antibody reacting with granulocytes, monocytes and haematopoietic progenitor cells. Br J Haematol. 1986; 64:363-73. Google Scholar20. Toth EL, Mant MJ, Shivji S, Ginsberg J. Propylthiouracil-induced agranulocytosis: an unusual presentation and a possible mechanism. Am J Med. 1988; 85:725-7. Google Scholar21. Wade WF, Davoust J, Salamero J, Andre P, Watts TH, Cambier JC. Structural compartmentalization of MHC class II signaling function. Immunol Today. 1993; 14:539-46. Google Scholar22. McDevitt HO. Regulation of the immune response by the major histocompatibility system. N Engl J Med. 1980; 303:1514-7. Google Scholar23. Brown JH, Jardetzky TS, Gorga JC, Stern LJ, Urban RG, Strominger JL, et al. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature. 1993; 364:33-9. Google Scholar24. Rammensee HG, Friede T, Stevanovic S. MHC ligands and peptide motifs: first listing. Immunogenetics. 1996; 41:178-228. Google Scholar25. Hammer J, Valsasnini P, Tolba K, Bolin D, Higelin J, Takacs B, et al. Promiscuous and allele-specific anchors in HLA-DR-binding peptides. Cell. 1993; 74:197-203. Google Scholar26. Chicz RM, Urban RG, Gorga JC, Vignali DA, Lane WS, Strominger JL. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med. 1993; 178:27-47. Google Scholar27. Todd JA, Acha-Orbea H, Bell JI, Chao N, Fronek Z, Jacob CO, et al. A molecular basis for MHC class II-associated autoimmunity. Science. 1988; 240:1003-9. Google Scholar28. Sasazuki T, Nishimura Y, Muto M, Ohta N. HLA-linked genes controlling immune response and disease susceptibility. Immunol Rev. 1983; 70:51-75. Google Scholar29. Kimura A, Sasazuki T. Eleventh International Histocompatibility Workshop reference protocol for the HLA DNA-typing technique. In: Tsuji K, Aizawa M, Sasazuki T, eds. HLA 1991. v 1. Oxford: Oxford Univ Pr; 1992:397-419. Google Scholar30. Kimura A, Dong RP, Harada H, Sasazuki T. DNA typing of HLA class II genes in B-lymphoblastoid cell lines homozygous for HLA. Tissue Antigens 1992; 40:5-12. Google Scholar31. Bodmer JG, Marsh SG, Albert ED, Bodmer WF, Dupont B, Erlich HA, et al. Nomenclature for factors of the HLA system, 1995. Tissue Antigens. 1995; 46:1-18. Google Scholar32. Imanishi T, Akaza T, Kimura A, Tokunaga K, Gojobori T. Allele frequencies and haplotype frequencies for HLA and complement loci in various ethnic groups. In: Tsuji K, Aizawa M, Sasazuki T, eds. HLA 1991. v 1. Oxford: Oxford Univ Pr; 1992:1065-220. Google Scholar33. Tiwari JL, Terasaki PI. HLA and Disease Associations. New York: Springer-Verlag; 214-20. Google Scholar34. Uno H, Sasazuki T, Tamai H, Matsumoto H. Two major genes, linked to HLA and Gm, control susceptibility to Graves' disease. Nature. 1981; 292:768-70. Google Scholar35. Dong RP, Kimura A, Okubo R, Shinagawa H, Tamai H, Nishimura Y, et al. HLA-A and DPB1 loci confer susceptibility to Graves' disease. Hum Immunol. 1992; 35:165-72. Google Scholar36. Tamai H, Kimura A, Dong RP, Matsubayashi S, Kuma K, Nagataki S, et al. Resistance to autoimmune thyroid disease is associated with HLA-DQ. J Clin Endocrinol Metab. 1994; 78:94-7. Google Scholar37. George AJ, Ritter MA, Lechler RI. Disease susceptibility, transplantation and the MHC. Immunol Today. 1995; 16:209-11. Google Scholar38. Krieger JI, Karr RW, Grey HM, Yu WY, O'Sullivan D, Batovsky L, et al. Single amino acid changes in DR and antigen define residues critical for peptide-MHC binding and T cell recognition. J Immunol. 1991; 146:2331-40. Google Scholar39. Marshall KW, Liu AF, Canales J, Perahia B, Jorgensen B, Gantzos RD, et al. Role of the polymorphic residues in HLA-DR molecules in allele-specific binding of peptide ligands. J Immunol. 1994; 152:4946-57. Google Scholar40. Fu XT, Bono CP, Woulfe SL, Swearingen C, Summers NL, Sinigaglia F, et al. Pocket 4 of the HLA-DR (α β 1*0401) molecule is a major determinant of T cells recognition of peptide. J Exp Med. 1995; 181:915-26. Google Scholar41. Matsushita S, Takahashi K, Motoki M, Komoriya K, Ikegawa S, Nishimura Y. Allele specificity of structural requirement for peptides bound to HLA-DRB1*0405 and -DRB1*0406 complexes: implication for the HLA-associated susceptibility to methimazole-induced insulin autoimmune syndrome. J Exp Med. 1994; 180:873-83. Google Scholar42. Takayama -Hasumi S, Eguchi Y, Sato A, Morita C, Hirata Y. Insulin autoimmune syndrome is the third leading cause of spontaneous hypoglycemic attacks in Japan. Diabetes Res Clin Pract. 1990; 10:211-4. Google Scholar43. Uchigata Y, Omori Y, Nieda M, Kuwata S, Tokunaga K, Juji T. HLA-DR4 genotype and insulin-processing in insulin autoimmune syndrome [Letter]. Lancet. 1992; 340:1467. Google Scholar44. Renoux G. The general immunopharmacology of levamizole. Drugs. 1980; 20:89-99. Google Scholar Author, Article, and Disclosure InformationAffiliations: From Kyushu University, Fukuoka, Japan; Tokyo Medical and Dental University, Tokyo, Japan; Kuma Hospital, Kobe, Japan; and Nagasaki University School of Medicine, Nagasaki, Japan.Grant Support: In part by the Ministry of Education, Culture, and Science, Japan; the Ministry of Health and Welfare, Japan; and the Naito Foundation.Corresponding Author: Hajime Tamai, MD, Department of Psychosomatic Medicine, Faculty of Medicine, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812, Japan.Current Author Addresses: Drs. Tamai, Mukuta, and Matsubayashi: Department of Psychosomatic Medicine, Faculty of Medicine, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812, Japan. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byEvolving Role of Pharmacogenetic Biomarkers to Predict Drug-Induced Hematological DisordersRare case of pancrelipase therapy-induced neutropaeniaHLA-B*39:01:01 is a novel risk factor for antithyroid drug-induced agranulocytosis in Japanese populationIdiosyncratic Drug-Induced Neutropenia and Agranulocytosis in Elderly PatientsAnalysis of the Implementation of Blood Tests Specified in the Package Insert After Prescription of ThiamazoleAssociations of HLA genotypes with antithyroid drug‐induced agranulocytosis: A systematic review and meta‐analysis of pharmacogenomics studiesIncreased Risk of Antithyroid Drug Agranulocytosis Associated with Amiodarone-Induced Thyrotoxicosis: A Population-Based Cohort StudyGraves' disease: Introduction, epidemiology, endogenous and environmental pathogenic factorsThyrotropin receptor antibodies and a genetic hint in antithyroid drug-induced adverse drug reactionsAssociation of HLA-B ∗ 38:02 with Antithyroid Drug-Induced Agranulocytosis in Kinh Vietnamese PatientsRecent updates and challenges on the regulation of precision medicine: The United States in perspectiveSulfasalazine-Induced Agranulocytosis Is Associated With the Human Leukocyte Antigen LocusBiomarkers of adverse drug reactionsHLAs: Key regulators of T-cell-mediated drug hypersensitivityNon–chemotherapy drug–induced neutropenia: key points to manage the challengesRare NOX3 Variants Confer Susceptibility to Agranulocytosis During Thyrostatic Treatment of Graves' DiseaseAssociation of HLA-B and HLA-DRB1 polymorphisms with antithyroid drug-induced agranulocytosis in a Han population from northern ChinaEpidemiology of Acquired Bone Marrow FailurePharmacogenetics and Predictive Testing of Drug Hypersensitivity ReactionsAgranulocytoses aux antithyroïdiens de synthèse : revue de la littératureGenetic variants associated with antithyroid drug-induced agranulocytosis: a genome-wide association study in a European populationFirst step towards precision medicine for antithyroid drug-induced agranulocytosisCan Genotyping Predict the Likelihood of Methimazole-Induced Agranulocytosis?ThionamidesHuman leukocyte antigen polymorphisms and personalized medicine for rheumatoid arthritisGenetic determinants of antithyroid drug-induced agranulocytosis by human leukocyte antigen genotyping and genome-wide association studyPhase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H 4 R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitisGenetics of Interstitial Lung Disease: Vol de Nuit (Night Flight)Nonchemotherapy Drug-Induced Neutropenia and AgranulocytosisCharacteristics of Agranulocytosis as an Adverse Effect of Antithyroid Drugs in the Second or Later Course of TreatmentHLA-DRB1*08:02 Is Associated with Bucillamine-Induced Proteinuria in Japanese Rheumatoid Arthritis PatientsSuccessful Treatment of Methimazole-Induced Severe Aplastic Anemia by Granulocyte Colony-Stimulating Factor, Methylprednisolone, and CyclosporinHyperthyroidism Due to Graves' Disease, Toxic Nodules and Toxic Multinodular GoiterIODINE AND DRUGS THAT AFFECT THYROID FUNCTIONA Case of Methimazole-induced Agranulocytosis and Kikuchi's Disease in a Patient with Graves' DiseasePharmacologic Management of Feline HyperthyroidismThe Relation of Initial Methimazole Dose to the Incidence of Methimazole-induced Agranulocytosis in Patients with Graves' DiseaseMedical Management of HyperthyroidismThionamidesAvaliação do tratamento clínico da doença de GravesThionamide-Induced Agranulocytosis Additional Cases of Diabetic Myonecrosis Nutrition Guidelines—A Welcome ResourceRetrospective Analysis of 18 Cases of Antithyroid Drug (ATD)-Induced Agranulocytosis.Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndromeThe Etiology of Acquired Aplastic AnemiaHLA and Endocrine DiseaseHematopoietic cell destruction by immune mechanisms in acquired aplastic anemiaAcute pancreatitis and parotitis induced by methimazole in a patient with Graves' diseaseMethimazole-Induced Aplastic Anemia in Third Exposure: Successful Treatment with Recombinant Human Granulocyte Colony-Stimulating FactorPolymorphism of the 5′-flanking region of the human tumor necrosis factor (TNF)-α gene in JapaneseANTITHYROID DRUGS FOR THE TREATMENT OF HYPERTHYROIDISM CAUSED BY GRAVES' DISEASEThyroid hormones and antithyroid drugsThe Pathophysiology of Acquired Aplastic Anemia 1 March 1996Volume 124, Issue 5Page: 490-494KeywordsAllelesAntibodiesAntigen-presenting cellsDNADrugsGranulocytesHuman leukocyte antigenLymphocytesMajor histocompatibility complexOdds ratio Issue Published: 1 March 1996 Copyright & PermissionsCopyright © 1996 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...